Collegium Pharma acquires Biodelivery Sciences International Inc., and with it Belbuca , Symproic and Elyxyb.
Collegium Pharmaceutical, Inc. and Biodelivery Sciences International, Inc. announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash.
BDSI has a portfolio of pain and neurology products that address serious and debilitating conditions. BDSI’s commercial growth driver, Belbuca, is a meaningfully differentiated schedule III opioid product and is highly complementary to Collegium’s portfolio of pain products. Additional products in the BDSI portfolio include Symproic, a contributor, and Elyxyb, a neurology product in its early launch phase.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins